Seeking Alpha
25 Jun 2026, 05:23 UTC · 13w ago
Verdict
Headline takes no side. We score VIR +0.80 across two claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Veligrotug has a set FDA PDUFA date of June 30, 2026, following pivotal Phase 3 data in active and chronic TED.
So whatA binary FDA decision on a pivotal Phase 3 asset is the primary driver of valuation for late-stage biotech companies.
More positive than 99% of claims this week
Viridian plans a BLA submission for Elegrobart, a subcutaneous follow-on asset, in Q1 2027.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 79% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company is transitioning to a commercial player with positive Phase 3 data and upcoming FDA milestones.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+5.6%
Price agrees with the score
$10.51 vs $9.95 close before publication (Jun 24) · not market-adjusted
VIR chart →
